There are several new injectable treatments for Multiple Sclerosis (MS), each with its own mechanism and administration method. The "newest" depends on the timeframe considered.
Newly Approved and Updated Treatments
-
Ublituximab-xiiy (Briumvi): Approved by the FDA in 2022, this intravenous injection targets specific immune system cells to reduce damage to the brain and spinal cord. It treats relapsing-remitting and active secondary-progressive MS.
-
Ocrelizumab (Ocrevus): Now available as a 10-minute subcutaneous injection, significantly reducing treatment time compared to previous infusion methods. This has been rolled out on the NHS and approved by the MHRA. It's a disease-modifying therapy (DMT) for active relapsing MS or early primary progressive MS.
-
Tyruko (natalizumab-sztn): Approved in 2023, this is the first biosimilar to Tysabri (natalizumab), offering an alternative injection for MS treatment.
-
Ofatumumab (Kesimpta): Approved by the FDA in 2020, this is a self-injectable treatment for relapsing-remitting and secondary-progressive MS.
Emerging Research
Research continues to explore novel therapies, including a drug developed by UCSF and Contineum Therapeutics that aims to repair the protective myelin sheath around nerves damaged by MS. This is still under development.
It's crucial to consult with a neurologist to determine the most suitable treatment for your specific MS type and condition. The information provided here should not be taken as medical advice.
